Tag: heart problems
-
December 2021 JAK Inhibitors Drug Class Label Changes: More Warnings and Use Restrictions
Risks of Cancers, Blood Clots, Heart Problems, and Deaths Associated with Xeljanz, Olumiant, and Rinvoq (Posted by Tom Lamb at Drug Injury Watch) As background, in September 2021 the FDA announced that it was requiring…
-
Eli Lilly Attempts to Distance Olumiant From the Ominous JAK Inhibitors Drug Class Safety Issues Flagged by FDA
Xeljanz, Rinvoq, and Olumiant Are the Three Janus Kinase (JAK) Inhibitors Getting "Black-Box" Warnings Revisions, Soon (Posted by Tom Lamb at Drug Injury Watch) In September 2021 the FDA announced it was requiring revisions to…
-
Lemtrada Use Restrictions Issued By EMA’s Pharmacovigilance Risk Assessment Committee Due To Safety Issues
Action Due To Reports Of Lemtrada Side Effects Including Deaths Related To Immune Complications And Heart Or Circulatory Disorders (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2019 the Pharmacovigilance Risk…
-
Various Drug Safety Issues Continue To Be Associated With Novartis Multiple Sclerosis (MS) Medication Gilenya
ISMP QuarterWatch Report From 2014 States Adverse Events Reports Show That Gilenya Cardiac Risks "were neither rare nor hypothetical" (Posted by Tom Lamb at DrugInjuryWatch.com)The safety profile for the Novartis drug Gilenya (fingolimod) has been controversial for…
-
Fresenius GranuFlo Product Has Been Associated With Heart Problems And Cardiopulmonary Arrest During Dialysis Treatment
Fresenius Failed To Warn About Risks Of Sudden Heart Attack, Stroke, And Death Caused By GranuFlo Increasing The Level Of Bicarbonate In Blood (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: Federal court GranuFlo…
-
Multaq: August 2011 Update: Another Liver Failure Case Report Article In Medical Journal
New Sanofi "Dear Doctor" Letter: Label Change Regarding Heart-Related Side Effects Coming Soon (Posted by Tom Lamb at DrugInjuryWatch.com)This August 2011 update on Multaq (dronedarone) covers both liver injury and cardiovascular side effects. The medical…
-
Multaq Update: European Safety Review Expanded To Cardiovascular Side Effects Risk In July 2011
EMA And FDA Already Had Sanofi Issue A "Dear Doctor" Letter About Liver Failure In January 2011 (Posted by Tom Lamb at DrugInjuryWatch.com) ______________________________________________________________________________ UPDATE: The FDA announced on July 21, 2011 that it…